Gigi Kenneth continues a series:
If you’re moving regulated analysis from SAS to R, two things are worth knowing up front. R is a choice you can defend: regulators don’t tell you which software to use, and R has already been through FDA review in public pilot submissions. And the language itself is the cheap part. Most of the cost and risk comes from six other places, and most of those are about planning, not programming.
Part one asked whether SAS is still worth keeping. This post covers why R, and where to put your budget and attention once you commit.
Click through for several notes that may trip up a migration, particularly in a clinical environment.